# Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

> **NCT00121992** · PHASE3 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 1060 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** 5-fluorouracil
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00121992
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2010-12-02
- **Final completion:** 2013-03-06
- **Target enrollment:** 1060 (ACTUAL)
- **Last updated:** 2023-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121992, "Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00121992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*